Why the study?
How do patient characteristics affect phenobarbitone clearance and dosing regimen estimation?
How do patient characteristics affect phenobarbitone clearance and dosing regimen estimation?
Population pharmacokinetic modeling using NONMEM allows for accurate prediction of steady-state phenobarbitone concentrations based on patient characteristics like body weight and concomitant medications.
Answers are grounded in this paper and cite their sources.
May guide weight-based phenobarbitone dosing in young children; leaves open prospective validation before practice change.
Routine clinical pharmacokinetic data collected from patients receiving phenobarbitone have been analysed to evaluate the role of patient characteristics for estimating dosing regimens. The data were analysed using NONMEM, a computer program designed for population pharmacokinetic analysis that allows pooling of data. The pharmacokinetic model of phenobarbitone was described using a one-compartment steady-state model. The effect of a variety of developmental and demographic factors on clearance was investigated. NONMEM estimates indicated a nonlinear function of total body weight as the optimum adjustment of phenobarbitone clearance. Concomitant administration of phenobarbitone and other antiepileptic drugs showed a decrease of phenobarbitone clearance in young children. The dosing method based on clearance values obtained by NONMEM analysis allowed the prediction of the steady-state concentration as a function of maintenance dose with acceptable error for therapeutic drug monitoring.
No takes yet. Share an insight, caveat, or question.
Yukawa et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: